Advertisement

The role of miRNA-339-5p in the function of vascular endothelial progenitor cells in patients with PCOS

Published:October 03, 2021DOI:https://doi.org/10.1016/j.rbmo.2021.09.017

      Abstract

      Research question

      miRNA-339 participates in diseases with endothelial progenitor cell (EPC) dysfunction. What is the role of miRNA-339-5p in EPC of polycystic ovary syndrome (PCOS)?

      Design

      Clinical data were collected from 76 controls and 84 PCOS patients. Noradrenaline, asymmetric dimethylarginine (ADMA), advanced glycation end products (AGE) and silent information regulator 1 (SIRT1) in the serum were measured. The functions of EPC and the expressions of PI3K, AKT, SIRT1 and PGC-1α in EPC before and after transfection with miRNA-339-5p analogue or miRNA-339-5p inhibitor were compared.

      Results

      Serum concentrations of noradrenaline, ADMA and AGE were significantly higher (P = 0.009, P = 0.044, P < 0.001) and the SIRT1 concentration was significantly lower (P < 0.001) in PCOS patients, especially obese ones (P = 0.034, P = 0.032, P < 0.001, P = 0.023) than in the control group. When compared with the controls, proliferation of the EPC was slightly lower (without a significant difference), the migration and tubular formation were significantly decreased (P = 0.037, P = 0.011), the expression of miRNA-339-5p in EPC was significantly higher (P = 0.035) and the expressions of PI3K, AKT, SIRT1 and PGC-1α were significantly lower in the PCOS group (mRNA: P = 0.033, P = 0.027, P = 0.027, P = 0.032; protein: P = 0.036, P = 0.028, P = 0.039, P = 0.023). After transfection, the functions of EPC from PCOS patients were best in the miRNA-339-5p inhibitor group, and weakest in the miRNA-339-5p mimic group. The miRNA-339-5p inhibitor group had higher protein expressions of PI3K, AKT and SIRT1 but lower expression of PGC-1α in PCOS patients (P < 0.001, P = 0.030, P = 0.047, P = 0.003). Similar results were obtained from the controls after transfection.

      Conclusion

      Increased sympathetic excitation and damage to EPC were observed in PCOS patients, especially obese ones. Up-regulated miRNA-339-5p could inhibit the function of EPC by inhibiting the PI3K/AKT and SIRT1/PGC-1α signalling pathways.

      Keywords

      To read this article in full you will need to make a payment

      References

        • Abdalla M.
        • Deshmukh H.
        • Atkin S.L.
        • Sathyapalan T.
        miRNAs as a novel clinical biomarker and therapeutic targets in polycystic ovary syndrome (PCOS): a review.
        Life Sci. 2020; 259118174
        • Chen B.
        • Xu P.
        • Wang J.
        • Zhang C.
        The role of miRNA in polycystic ovary syndrome (PCOS).
        Gene. 2019; 706: 91-96
        • Chen Z.
        • Ou H.
        • Wu H.
        • Wu P.
        • Mo Z.
        Role of microRNA in the pathogenesis of polycystic ovary syndrome.
        DNA Cell Biol. 2019; 38: 754-762
        • Choi E.
        • Cha M.J.
        • Hwang K.C.
        Roles of calcium regulating microRNAs in cardiac ischemia-reperfusion injury.
        Cells. 2014; 3: 899-913
        • Cohen C.R.
        • Diel V.B.
        • La Porta V.L.
        • Rohde L.E.
        • Biolo A.
        • Clausell N.
        • Dos S.K.
        Association study of polymorphisms in the receptor for advanced glycation end-products (RAGE) gene with susceptibility and prognosis of heart failure.
        Gene. 2012; 510: 7-13
        • Crespo R.P.
        • Bachega T.
        • Mendonca B.B.
        • Gomes L.G.
        An update of genetic basis of PCOS pathogenesis.
        Arch. Endocrinol. Metab. 2018; 62: 352-361
        • de Groot P.C.
        • Dekkers O.M.
        • Romijn J.A.
        • Dieben S.W.
        • Helmerhorst F.M.
        PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analysis.
        Hum. Reprod. Update. 2011; 17: 495-500
        • Derda A.A.
        • Pfanne A.
        • Bar C.
        • Schimmel K.
        • Kennel P.J.
        • Xiao K.
        • Schulze P.C.
        • Bauersachs J.
        • Thum T.
        Blood-based microRNA profiling in patients with cardiac amyloidosis.
        PLoS One. 2018; 13e204235
        • Ding D.C.
        • Tsai I.J.
        • Wang J.H.
        • Lin S.Z.
        • Sung F.C.
        Coronary artery disease risk in young women with polycystic ovary syndrome.
        Oncotarget. 2018; 9: 8756-8764
        • Dokras A.
        Cardiovascular disease risk in women with PCOS.
        Steroids. 2013; 78: 773-776
        • Dokras A.
        • Jagasia D.H.
        • Maifeld M.
        • Sinkey C.A.
        • Vanvoorhis B.J.
        • Haynes W.G.
        Obesity and insulin resistance but not hyperandrogenism mediates vascular dysfunction in women with polycystic ovary syndrome.
        Fertil. Steril. 2006; 86: 1702-1709
        • Esler M.
        • Straznicky N.
        • Eikelis N.
        • Masuo K.
        • Lambert G.
        • Lambert E.
        Mechanisms of sympathetic activation in obesity-related hypertension.
        Hypertension. 2006; 48: 787-796
        • Gerhart-Hines Z.
        • Rodgers J.T.
        • Bare O.
        • Lerin C.
        • Kim S.H.
        • Mostoslavsky R.
        • Alt F.W.
        • Wu Z.
        • Puigserver P.
        Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1alpha.
        EMBO J. 2007; 26: 1913-1923
        • Grosse G.M.
        • Schwedhelm E.
        • Worthmann H.
        • Choe C.U.
        Arginine derivatives in cerebrovascular diseases: mechanisms and clinical implications.
        Int. J. Mol. Sci. 2020; 21: 1798
        • Han W.
        • Cui H.
        • Liang J.
        • Su X.
        Role of MicroRNA-30c in cancer progression.
        J. Cancer. 2020; 11: 2593-2601
        • Hu M.H.
        • Zheng S.X.
        • Yin H.
        • Zhu X.Y.
        • Lu F.T.
        • Tong X.H.
        • Liu Y.S.
        • Zhang Y.W.
        • Xu B.
        Identification of microRNAs that regulate the MAPK pathway in human cumulus cells from PCOS women with insulin resistance.
        Reprod. Sci. 2020; 27: 833-844
        • Jiang L.
        • Huang J.
        • Li L.
        • Chen Y.
        • Chen X.
        • Zhao X.
        • Yang D.
        MicroRNA-93 promotes ovarian granulosa cells proliferation through targeting CDKN1A in polycystic ovarian syndrome.
        J. Clin. Endocrinol. Metab. 2015; 100: E729-E738
        • Kaur R.
        • Kaur T.
        • Kaur A.
        Genetic association study from North India to analyse association of CYP19A1 and CYP17A1 with polycystic ovary syndrome.
        J. Assist. Reprod. Genet. 2018; 35: 1123-1129
        • Lagouge M.
        • Argmann C.
        • Gerhart-Hines Z.
        • Meziane H.
        • Lerin C.
        • Daussin F.
        • Messadeq N.
        • Milne J.
        • Lambert P.
        • Elliott P.
        • Geny B.
        • Laakso M.
        • Puigserver P.
        • Auwerx J.
        Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha.
        Cell. 2006; 127: 1109-1122
        • Lambert E.A.
        • Teede H.
        • Sari C.I.
        • Jona E.
        • Shorakae S.
        • Woodington K.
        • Hemmes R.
        • Eikelis N.
        • Straznicky N.E.
        • De Courten B.
        • Dixon J.B.
        • Schlaich M.P.
        • Lambert G.W.
        Sympathetic activation and endothelial dysfunction in polycystic ovary syndrome are not explained by either obesity or insulin resistance.
        Clin. Endocrinol. (Oxf.). 2015; 83: 812-819
        • Li P.
        • Liu H.
        • Li Y.
        • Wang Y.
        • Zhao L.
        • Wang H.
        miR-339-5p inhibits lung adenocarcinoma invasion and migration by directly targeting BCL6.
        Oncol. Lett. 2018; 16: 5785-5790
        • Li W.
        • Du D
        • Wang H.
        • Liu Y.
        • Lai X.
        • Jiang F.
        • Chen D.
        • Zhang Y.
        • Zong J.
        • Li Y.
        Silent information regulator 1 (SIRT1) promotes the migration and proliferation of endothelial progenitor cells through the PI3K/Akt/eNOS signaling pathway.
        Int. J. Clin. Exp. Pathol. 2015; 8: 2274-2287
        • Liang D.
        • Zhuo Y.
        • Guo Z.
        • He L.
        • Wang X.
        • He Y.
        • Li L.
        • Dai H.
        SIRT1/PGC-1 pathway activation triggers autophagy/mitophagy and attenuates oxidative damage in intestinal epithelial cells.
        Biochimie. 2020; 170: 10-20
        • Lin F.
        • Yang Y.
        • Wei S.
        • Huang X.
        • Peng Z.
        • Ke X.
        • Zeng Z.
        • Song Y.
        Hydrogen sulfide protects against high glucose-induced human umbilical vein endothelial cell injury through activating PI3K/Akt/eNOS pathway.
        Drug Des Devel Ther. 2020; 14: 621-633
        • Lionett S.
        • Kiel I.A.
        • Camera D.M.
        • Vanky E.
        • Parr E.B.
        • Lydersen S.
        • Hawley J.A.
        • Moholdt T.
        Circulating and adipose tissue miRNAs in women with polycystic ovary syndrome and responses to high-intensity interval training.
        Front Physiol. 2020; 11: 904
        • Luo Y.
        • Cui C.
        • Han X.
        • Wang Q.
        • Zhang C.
        The role of miRNAs in polycystic ovary syndrome with insulin resistance.
        J. Assist. Reprod. Genet. 2021; 38: 289-304
        • Makinen P.I.
        • Koponen J.K.
        • Karkkainen A.M.
        • Malm T.M.
        • Pulkkinen K.H.
        • Koistinaho J.
        • Turunen M.P.
        • Yla-Herttuala S.
        Stable RNA interference: comparison of U6 and H1 promoters in endothelial cells and in mouse brain.
        J. Gene. Med. 2006; 8: 433-441
        • Ollila M.M.
        • Piltonen T.
        • Puukka K.
        • Ruokonen A.
        • Jarvelin M.R.
        • Tapanainen J.S.
        • Franks S.
        • Morin-Papunen L.
        Weight gain and dyslipidemia in early adulthood associate with polycystic ovary syndrome: prospective cohort study.
        J. Clin. Endocrinol. Metab. 2016; 101: 739-747
        • Olmos Y.
        • Sanchez-Gomez F.J.
        • Wild B.
        • Garcia-Quintans N.
        • Cabezudo S.
        • Lamas S.
        • Monsalve M.
        SirT1 regulation of antioxidant genes is dependent on the formation of a FoxO3a/PGC-1alpha complex.
        Antioxid. Redox Signal. 2013; 19: 1507-1521
        • Ota H.
        • Akishita M.
        • Eto M.
        • Iijima K.
        • Kaneki M.
        • Ouchi Y.
        SirT1 modulates premature senescence-like phenotype in human endothelial cells.
        J. Mol. Cell Cardiol. 2007; 43: 571-579
        • Palomba S.
        • Santagni S.
        • Falbo A.
        • La Sala B.G.
        Complications and challenges associated with polycystic ovary syndrome: current perspectives.
        Int. J. Womens Health. 2015; 7: 745-763
        • Pinola P.
        • Puukka K.
        • Piltonen T.T.
        • Puurunen J.
        • Vanky E.
        • Sundstrom-Poromaa I.
        • Stener-Victorin E.
        • Linden H.A.
        • Ravn P.
        • Skovsager A.M.
        • Glintborg D.
        • Mellembakken J.R.
        • Ruokonen A.
        • Tapanainen J.S.
        • Morin-Papunen L.C.
        Normo- and hyperandrogenic women with polycystic ovary syndrome exhibit an adverse metabolic profile through life.
        Fertil. Steril. 2017; 107: 788-795
        • Qin S.
        • Tian H.
        • Wei J.
        • Han Z.
        • Zhang M.
        • Hao G.
        • Liu X.
        • Pan L.
        3-bromo-4,5-dihydroxybenzaldehyde protects against myocardial ischemia and reperfusion injury through the Akt-PGC1α-Sirt3 pathway.
        Front Pharmacol. 2018; 9: 722
        • Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group
        Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.
        Fertil. Steril. 2004; 81: 19-25
        • Schlaich M.P.
        • Straznicky N.
        • Grima M.
        • Ika-Sari C.
        • Dawood T.
        • Mahfoud F.
        • Lambert E.
        • Chopra R.
        • Socratous F.
        • Hennebry S.
        • Eikelis N.
        • Bohm M.
        • Krum H.
        • Lambert G.
        • Esler M.D.
        • Sobotka P.A.
        Renal denervation: a potential new treatment modality for polycystic ovary syndrome?.
        J. Hypertens. 2011; 29: 991-996
        • Shan W.
        • Li J.
        • Bai Y.
        • Lu X.
        miR-339-5p inhibits migration and invasion in ovarian cancer cell lines by targeting NACC1 and BCL6.
        Tumour Biol. 2016; 37: 5203-5211
        • Sorensen M.B.
        • Franks S.
        • Robertson C.
        • Pennell D.J.
        • Collins P.
        Severe endothelial dysfunction in young women with polycystic ovary syndrome is only partially explained by known cardiovascular risk factors.
        Clin. Endocrinol. (Oxf.). 2006; 65: 655-659
        • Sverrisdottir Y.B.
        • Mogren T.
        • Kataoka J.
        • Janson P.O.
        • Stener-Victorin E.
        Is polycystic ovary syndrome associated with high sympathetic nerve activity and size at birth?.
        Am. J. Physiol. Endocrinol. Metab. 2008; 294: E576-E581
        • Tan S.
        • Li S.
        • Min Y.
        • Gistera A.
        • Moruzzi N.
        • Zhang J.
        • Sun Y.
        • Andersson J.
        • Malmstrom R.E.
        • Wang M.
        • Berggren P.O.
        • Schlisio S.
        • Liao W.
        • Ketelhuth D.
        • Ma C.
        • Li N.
        Platelet factor 4 enhances CD4(+) T effector memory cell responses via Akt-PGC1alpha-TFAM signaling-mediated mitochondrial biogenesis.
        J. Thromb. Haemost. 2020; 18: 2685-2700
        • van der Heijden D.J.
        • van Leeuwen M.
        • Janssens G.N.
        • Lenzen M.J.
        • van de Ven P.M.
        • Eringa E.C.
        • van Royen N.
        Body mass index is associated with microvascular endothelial dysfunction in patients with treated metabolic risk factors and suspected coronary artery disease.
        J. Am. Heart Assoc. 2017; 6e006082
        • Villena J.A.
        New insights into PGC-1 coactivators: redefining their role in the regulation of mitochondrial function and beyond.
        Febs. J. 2015; 282: 647-672
        • Virdis A.
        • Masi S.
        • Colucci R.
        • Chiriaco M.
        • Uliana M.
        • Puxeddu I.
        • Bernardini N.
        • Blandizzi C.
        • Taddei S.
        Microvascular endothelial dysfunction in patients with obesity.
        Curr. Hypertens Rep. 2019; 21: 32
        • Wan J.
        • Liu S.
        miR-613 inhibits the proliferation of human ovarian granulosa cells by arresting cell cycle progression via the targeting of IGF-1.
        Mol. Med. Rep. 2021; 23: 178
        • Wan Y.Z.
        • Gao P.
        • Zhou S.
        • Zhang Z.Q.
        • Hao D.L.
        • Lian L.S.
        • Li Y.J.
        • Chen H.Z.
        • Liu D.P.
        SIRT1-mediated epigenetic downregulation of plasminogen activator inhibitor-1 prevents vascular endothelial replicative senescence.
        Ageing Cell. 2014; 13: 890-899
        • Wang J.Y.
        • Li H.
        • Ma C.M.
        • Wang J.L.
        • Lai X.S.
        • Zhou S.F.
        MicroRNA profiling response to acupuncture therapy in spontaneously hypertensive rats.
        Evid. Based Complement Alternat. Med. 2015; 2015204367
        • Wild R.A.
        • Carmina E.
        • Diamanti-Kandarakis E.
        • Dokras A.
        • Escobar-Morreale H.F.
        • Futterweit W.
        • Lobo R.
        • Norman R.J.
        • Talbott E.
        • Dumesic D.A.
        Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society.
        J. Clin. Endocrinol. Metab. 2010; 95: 2038-2049
        • Xu F.
        • Na L.
        • Li Y.
        • Chen L.
        Roles of the PI3K/AKT/mTOR signalling pathways in neurodegenerative diseases and tumours.
        Cell Biosci. 2020; 10: 54
        • Zhang W.
        • Huang Q.
        • Zeng Z.
        • Wu J.
        • Zhang Y.
        • Chen Z.
        Sirt1 inhibits oxidative stress in vascular endothelial cells.
        Oxid. Med. Cell Longev. 2017; 20177543973
        • Zhang X.Z.
        • Pang Y.L.
        • Wang X.
        • Li Y.H.
        Computational characterization and identification of human polycystic ovary syndrome genes.
        Sci. Rep. 2018; 8: 12949
        • Zhao L.
        • Zhu Z.
        • Lou H.
        • Zhu G.
        • Huang W.
        • Zhang S.
        • Liu F.
        Polycystic ovary syndrome (PCOS) and the risk of coronary heart disease (CHD): a meta-analysis.
        Oncotarget. 2016; 7: 33715-33721
        • Zheng M.
        • Chen Y.
        • Park J.
        • Song H.C.
        • Chen Y.
        • Park J.W.
        • Joe Y.
        • Chung H.T.
        CO ameliorates endothelial senescence induced by 5-fluorouracil through SIRT1 activation.
        Arch. Biochem. Biophys. 2019; 677108185
        • Zhu F.
        • Zhou C.
        • Wen Z.
        • Wang D.W.
        DDAH1 promoter -396 4N insertion variant is associated with increased risk of type 2 diabetes in a gender-dependent manner.
        Mol. Genet. Genomic Med. 2020; 8: e1011

      Biography

      Juan Gui is a doctor and a researcher at the Reproductive Medicine Center, Renmin Hospital of Wuhan University, China. Her main research interests are focused on reproductive medicine, especially polycystic ovary syndrome.
      Key message
      The aim of this study including 76 controls and 84 PCOS patients was to evaluate the functions of EPC. Increased sympathetic excitation and damage to EPC were observed in PCOS patients, especially obese ones. miRNA-339-5p could regulate the functions of EPC through inhibiting the PI3K/AKT and SIRT1/PGC-1α signalling pathways and may be a target for improving the function of endothelial cells in PCOS patients.